Clinical Trial Update: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating frontline ibrutinib plus rituximab in unfit chronic lymphocytic leukemia has completed, assessing activity and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Lymphocyte Leukemia, Adult Patients | Phase 2 | Status: COMPLETED